NovaSom Announces New CEO John Spitznagel Experienced executive to lead aggressive commercialization and growth of in-home testing for Obstructive Sleep Apnea Business Wire GLEN BURNIE, Md. -- July 16, 2013 NovaSom, Inc., a leader in home sleep testing solutions for Obstructive Sleep Apnea (OSA), appointed John Spitznagel as the Company’s new CEO, effective immediately, as well as a member of the Board of Directors. Mr. Spitznagel brings more than 45 years of experience as a successful healthcare executive, with extensive knowledge of commercialization and growth strategies. Mr. Spitznagel will succeed Richard Hassett, M.D., who has served as President and CEO since 2010, and was responsible for overseeing the launch of AccuSom^®, the first FDA-cleared wireless home sleep test, in 2011. “NovaSom offers the best home sleep test available in the market today,” said Jim Datin, NovaSom Board Member. “We are excited that John is joining the NovaSom team. His experience in building successful commercialization programs is exactly what we need at this time for the future success of the NovaSom’s AccuSom Home Sleep Test. John will help make this test available to the millions of consumers who need to be tested—and treated—for OSA.” Mr. Spitznagel has a long track record of success in the healthcare industry. Prior to joining NovaSom, Mr. Spitznagel served as Chairman and CEO of Oceana Therapeutics, Inc., a medical device company focused on pediatric urology and colon and rectal surgery. Under Spitznagel’s guidance, the Company grew sales of its marketed product for vesicoureteral reflux and completed the clinical development program and PMA submission for Solesta, its fecal incontinence product. In December of 2011, Oceana was purchased by Salix Pharmaceuticals. Prior to Oceana, Mr. Spitznagel served as Chairman and CEO for Esprit Pharma, Inc., a specialty pharmaceutical company focused on the genito-urinary market. He oversaw Esprit’s growth from a start-up in 2005 to its purchase by Allergan, Inc. in 2007.Prior to that, Mr. Spitznagel was Chairman & CEO of ESP Pharma, a company he co-founded to pursue the acquisition, development and marketing of acute-care pharmaceuticals. Mr. Spitznagel led ESP’s rapid growth in sales and profitability, leading to ESP’s acquisition. Before ESP, Mr. Spitznagel was President & CEO of Roberts Pharmaceutical, which specialized in acquiring in-market and late-stage development drugs. He joined Roberts in 1996 and led the Company through a dramatic turnaround in profitability and the successful merger into Shire plc. Mr. Spitznagel also served as President of the Reed and Carnrick division of Block Drug from. He began his career at Warner-Lambert in sales and marketing and spent nearly ten years at Hoffmann-La Roche and ten years at American Home Products where he was Senior Vice President of Marketing and Sales for Wyeth. “NovaSom is uniquely positioned in the market to meet the changing needs of patients, physicians and sleep centers,” said Spitznagel. “We have a terrific solution for in-home testing of OSA and the ability to help millions of people live a healthier life. Once it is recognized how easy and convenient testing can be, we are confident that AccuSom will quickly become the in-home test of choice.” About NovaSom, Inc. NovaSom, Inc. is a market leader in Obstructive Sleep Apnea (OSA) home testing, with the AccuSom^® Home Sleep Test, the first and only FDA-cleared wireless HST. The NovaSom home sleep testing technology and MediTrack^® portal have been shown to provide in-home, clinically equivalent diagnosis of OSA at a significantly reduced cost as compared to in-facility testing for uncomplicated, adult OSA. NovaSom's home sleep tests are currently covered for more than 150 million commercially insured U.S. lives. NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider and is classified by CMS as an Independent Diagnostic Testing Facility. For more information, visit www.NovaSom.com. Contact: Zer0 to 5ive Alyson Kuritz, 908-892-7149
NovaSom Announces New CEO John Spitznagel
Press spacebar to pause and continue. Press esc to stop.